Business Wire

UserTesting Grows EMEA Customer Base 400% in First Year; Sees a 750% Increase in Employee Headcount

2.9.2020 11:00:00 EEST | Business Wire | Press release

Share

UserTesting, a leading provider of on-demand human insights, has today announced a 400 percent customer growth in EMEA since opening its European headquarters in Edinburgh last July.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005297/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

UserTesting EMEA Growth 2020 (Graphic: Business Wire)

The huge growth has been as a direct result of changing consumer needs, perspectives, and behaviours caused by COVID-19, with brands and companies realising they must quickly relearn their customers, and do it remotely.

During the past year, UserTesting has gained over 100 new customers, including Brewin Dolphin, Depop, Post Office, Trussle, and HelloFresh–the leading meal-kit provider headquartered in Berlin. They join other well known European brands such as ASOS, Deliveroo, and Skyscanner, all of which are now embarking on their customer empathy journey with UserTesting.

Rapid customer insights

“UserTesting has cut our testing time in half, which has enabled us to scale testing and grow our UX Research team,” said James Villacci, Associate Director of UX Research at HelloFresh. “The level of support we've received has been tremendous, to the point that we see UserTesting more as a research partner. Prior to UserTesting, we were limited in how we could gather customer feedback, but now we can gain customer insights rapidly on a global level.”

To support its growing customer base across Europe, UserTesting has been building out its European talent, with an 8x growth in headcount–growing from 9 to 79 in just one year’s time and now with offices in Edinburgh, London, Berlin, and Oslo. This includes the recent acquisition of Teston, a European provider of multilingual experience testing for fast customer feedback in English, Norwegian, Swedish, German, French, and Danish.

Scottish CSR initiatives

UserTesting is also investing in Scotland’s tech community through two recent initiatives. UserTesting is supporting the charity Scotland Women in Technology (SWiT) via Hearts Women, and is also donating access to its platform to help enable the Scottish Tech Army to get fast feedback and insights on their technology projects, which are helping Scottish businesses that have been badly affected by COVID-19.

“We have one Scottish Tech Army team working on the public launch of a COVID-19 dashboard, and another team creating a product to allow our PPE Inventory Management service to be deployed to multiple charities and other organisations who are facing this logistical challenge,” said Andrew Rendle, Volunteer Project Manager, Scottish Tech Army.

Rendle added: “Without access to the UserTestingⓇ Platform, we would be relying on conventional wisdom and traditional testing approaches to design the interface, but thanks to UserTesting, we’ve been able to get in front of our intended audiences to collect the needed feedback to design the best user experience.”

About UserTesting

UserTesting enables every organization to deliver the best customer experience powered by human insight. With UserTesting’s on-demand Human Insight Platform, companies across industries make accurate customer-first decisions at every level, at the speed business demands. With UserTesting, product teams, marketers, digital, and customer experience executives, designers and UX researchers confidently and quickly create the right experiences for all target audiences, increasing brand loyalty and revenue. UserTesting has more than 1,500 subscription customers, including more than half of the world’s top brands, and has delivered human insights to over 35,000 companies to-date. UserTesting is headquartered in San Francisco, CA. To learn more, visit www.usertesting.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
UserTesting, Inc.
Chris Halcon
415-699-0553
chalcon@usertesting.com

UK Media Contact:
UserTesting, Inc.
Amy Kelly
+44 (0)77 1862 3019
akelly@usertesting.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye